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Background: Patients with primary cutaneous melanomas that are ulcerated and >2 mm in thickness, >4 mm in
thickness and those with nodal micrometastases at diagnosis, have few options for adjuvant treatment. Recent
studies have suggested a role for vitamin D to delay melanoma recurrence and improve overall prognosis.
Methods/Design: This is a pilot placebo-controlled randomised phase II trial to assess the feasibility, safety and
toxicity of an oral loading dose of Vitamin D (500,000 IU) followed by an oral dose of 50,000 IU of Vitamin D
monthly for 2 years in patients who have been treated for cutaneous melanoma by wide excision of the primary.
Patients aged 18 – 79 years who have completed primary surgical treatment and have Stage IIb, IIc, IIIa (N1a, N2a)
or IIIb (N1a, N2a) disease are eligible for randomisation 2:1 to active treatment or placebo. The primary endpoints are
sufficiency of dose, adherence to study medication and safety of the drug. The secondary endpoints are participation
and progression free survival. The study has been approved by the Ethics Review Committee (RPAH Zone) of the
Sydney Local Health District, protocol number X09-0138.
Discussion: Effective, non-toxic adjuvant therapy for high risk primary melanoma is not currently available. Favorable
outcomes of this phase II study will form the basis for a multi-centre phase III study to assess whether the addition of
oral high-dose vitamin D therapy in patients who have completed primary treatment for melanoma and are at high risk
of recurrence will:
1. prolong time to recurrence within 5 years
2. improve overall survival at 5 years and
3. be both safe and tolerable.
Target accrual for the study has been met with 75 patients randomised between December 2010 and August 2014.
The Mel-D trial is conducted by the Australia and New Zealand Melanoma Trials Group (ANZMTG 02.09).
Trial registration: Australia and New Zealand Clinical Trials Registry (ANZCTR) ACTRN12609000351213
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Table 1 TNM classification for CM (3)
Classification Thickness (mm) Ulceration status/
Mitoses
Tis N/A a N/A
T1 Without ulceration
and mitosis <1/mm2
b With ulceration or
mitosis ≥1/mm2
T2 1.01-2.00 a Without ulceration
b With ulceration
T3 2.01-4.00 a Without ulceration
b With ulceration
T4 >4.00 a Without ulceration
b With ulceration
N No. metastatic nodes Nodal metastatic
burden
N0 0 a N/A
N1 1 node involved Micrometastases*
1 node involved b Macrometastases†
N2 2-3 nodes involved a Micrometastases




N3 4+ metastatic nodes or
matted nodes or intransit
metastases/satellites with
metastatic nodes
M Site Serum LDH
M0 No distant metastases N/A
M1a Distant skin, subcutaneous
or nodal metastases
Normal
M1b Lung metastases Normal
M1c All other visceral metastases Normal
Any distant metastasis Elevated
*Micrometastases are diagnosed after sentinel lymph node biopsy.
†Macrometastases are defined as clinically detectable nodal metastases
confirmed pathologically.
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Cutaneous melanoma (CM) is the fourth most com-
monly diagnosed cancer in Australia, with an incidence
of 61.7 cases per 100,000 men, and 40.0 cases per
100,000 women in 2009. There are more than 12,500
new cases of melanoma diagnosed in Australia every
year and the diagnosis rates have doubled in the past
20 years. CM is the sixth most common cancer in the
United States, with an incidence of 21.3 per 100,000 per
year (with an incidence of 35.8 cases per 1000,000 in
men and 24.5 cases per 100,000 in women in 2011) [1].
Melanoma makes up only 2.3% of all skin cancers but is
responsible for 75% of skin cancer deaths. It is also the
most common form of cancer for people aged 15 to
44 years in Australia and accounts for more cancer re-
lated deaths in 20–34 year-olds Australians than any
other cancer [2].
Since the mid-1960s, CM incidence has risen 3-8% per
year in people of European background, with the great-
est increases in elderly men [3]. Although there has been
progressive improvement in 5 year survival, which is
now greater than 85%, CM causes disproportionate mor-
tality in those of young and middle age. Patients with ul-
cerated tumors thicker than 2 mm, with tumors thicker
than 4 mm or with nodal micro-metastases at diagnosis
(AJCC Stages IIb, IIc, IIIa (N1a, N2a) and IIIb (N1a,
N2a); Tables 1 and 2) have a relatively poor prognosis




Vitamin D is a fat-soluble seco-steroid, which acts in the
maintenance of calcium and phosphate homeostasis pre-
dominantly through increasing gut absorption of cal-
cium and phosphate. Vitamin D is derived from 2
sources – endogenous (from synthesis in the skin – vita-
min D3) and exogenous (dietary or supplements - vita-
mins D2 and D3). The substrate, 7-dehydrocholesterol
(7-DHC), the penultimate compound in the cholesterol
synthesis pathway, accumulates in the epidermis [4,5].
Ultraviolet B radiation to the skin transforms 7-DHC to
previtamin D3, which undergoes nonenzymatic isomeri-
sation to form vitamin D3. Vitamin D3 is transferred into
the blood stream by the vitamin D binding protein, an
α‐globulin that has a high affinity to vitamin D and its
metabolites.
To be physiologically active, vitamin D (either D2 or
D3) must first be hydroxylated to 25-hydroxyvitamin D
(25OHD), predominantly in the liver and 25OHD then
to 1α,25‐dihydroxyvitamin D (1α,25OHD), predomin-
antly in the kidneys for export into the bloodstream,
though many tissues, including skin, have the capacity to
produce 1α,25OHD. Figure 1 shows the physiology ofvitamin D in detail [6]. However, vitamin D can be activated
by other pathways to metabolites which do not raise serum
calcium [7].Serum measurement of vitamin D
Serum 1α,25OHD has a very short half-life and is not a
good measure of vitamin D status [8]. Serum 25OHD is
the main circulating form of vitamin D. It is relatively
stable [9], has a long half-life (τ1/2 = 18.9 +/− 3.1 days)
[10] and provides the substrate for local production of
the active hormone, 1α,25OHD and is therefore consid-
ered the best indicator of vitamin D status [11].
Table 2 AJCC pathological staging system for CM (3)






Stage 0 Tis N0 M0
Stage IA T1a N0 M0
Stage IB T1b N0 M0
T2a N0 M0
Stage IIA T2b N0 M0
T3a N0 M0
Stage IIB T3b N0 M0
T4a N0 M0
Stage IIC T4b N0 M0
Stage IIIA T1-4a N1a M0
T1-4a N2a M0





Stage IIIC T1-4b N1b M0
T1-4b N2b M0
T1-4b N2c M0
Any T N3 M0
Stage IV Any T Any N M1a
Any T Any N M1b
Any T Any N M1c
Figure 1 Physiology of vitamin D.
Saw et al. BMC Cancer 2014, 14:780 Page 3 of 10
http://www.biomedcentral.com/1471-2407/14/780Vitamin D and mortality
A meta‐analysis of 18 randomised trials of supplementa-
tion with vitamin D provided evidence that supplemen-
tal doses in the range of 7.5 to 50 μg per day could
significantly decrease all‐cause mortality. The summary
relative risk for mortality from any cause was 0.93 (95%
confidence interval, 0.87-0.99) [12]. The contribution of
specific causes of mortality to the reduction in all‐cause
mortality remains unknown.
Vitamin D and cancer including melanoma
1α,25OHD exerts physiological functions including regu-
lation of growth and differentiation in a broad variety of
normal and malignant cells [13-20] including melanoma
[21]. The first study to report anti-melanoma activity by
vitamin D showed in vitro, that 1α,25OHD inhibits cellular
proliferation, and promotes differentiation and apoptosis,
all properties compatible with antineoplastic action [22]. A
recent study has also shown some novel hydroxyvitamin D
analogues inhibit proliferation and colony formation of
melanoma cells, similar to 1α,25OHD [7]. Slightly supra-
physiological concentrations of 1α,25OHD have majoreffects on the cell cycle with a general but not complete
G0/G1 cycle arrest [23].
Melanoma cells are able to convert the main circulat-
ing form of vitamin D, 25OHD, to 1α,25OHD [24], thus
increasing the probability that vitamin D might be able
to regulate their growth in vivo. This discovery has led
to the hypothesis that autocrine or paracrine production
of 1α,25OHD could prevent some cancers (e.g., prostate,
colon, breast, pancreas, and ovary) and attenuate their
progression. Together, these elements support the hy-
pothesis that high serum 25OHD status could decrease
the risk of cancer.
At least in part, because sun exposure, particularly
intermittent exposure, is a risk factor for melanoma and
sun exposure also increases vitamin D synthesis, there
are no clear data relating 25OHD concentrations to risk
of melanoma [25,26]. However, there are additional ob-
servational data which supports the proposal that the
vitamin D system or vitamin D status may affect the risk
of melanoma and/or melanoma outcomes. Although the
data are by no means entirely consistent, a recent meta-
analysis showed that polymorphisms at two sites in the
vitamin D receptor were associated with either reduced
(Bsm 1 A allele) or increased (Fok 1 T allele) risk of mel-
anoma [27]. Poorer outcomes from melanoma have been
shown with melanoma cells that exhibit reduced or
complete loss of vitamin D receptors or cytochrome
P27B1 (CPY27B1 hydroxylates 25OHD) [28,29]. Further-
more, in a post-hoc sub-group analysis of the Women’s
Health Initiative randomized controlled trial, subjects
with a history of non-melanoma skin cancer who were
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400 IU of vitamin D per day had a reduced risk of mel-
anoma (HR 0.43: CI0.1-0.90; Pinteraction = 0.38) [30]. This
was not seen in whole group analyses. In terms of out-
comes, patients with melanomas surrounded by high
solar elastosis [31] and those diagnosed in summer [32]
show higher 5-year survival rates. Both of these factors
could be related to higher prevailing 25OHD levels, but
other interpretations are possible. Melanomas in patients
with higher 25OHD concentrations around the time of
diagnosis tend to have a lower Breslow thickness [27,33],
which is associated with a more favourable outcome.
Furthermore, in observational studies of patients with
melanoma, low 25OHD was associated with worse out-
comes [34] and low 25OHD at the time of diagnosis was
associated with an increased risk of progression and
death over the subsequent 5 years [33]. While these
findings are suggestive, the only way to determine
whether increasing vitamin D status will improve melan-
oma outcomes is by conducting a randomized controlled
trial [35]. However, several issues need to be addressed
before a full scale trial is undertaken.
Raising 25OHD concentrations
Vitamin D supplements, usually in the form of vitamin
D3, are used to raise 25OHD concentrations. When given
at a standard dose of 25 or 50 μg (1000 or 2000 IU) per
day, 25OHD concentrations take approximately 3 months
to reach a plateau [36] and compliance with daily dosing
is known to be problematic [37]. Bacon et al. suggested a
dosing protocol of a loading dose of 12.5 mg (500,000 IU)
of vitamin D3 followed by a monthly dose of 1.25 mg
(50,000 IU) as a way to achieve an early increase in
25OHD concentrations and improve the likelihood of
good compliance over the subsequent trial period, without
causing hypercalcemia [38]. Although a high yearly dose
of vitamin D of 12.5 mg in older women has been re-
ported to be associated with an increase in falls over the
subsequent 3 month period [39], no plausible mechanism
has yet been determined, so that in the case of melanoma
patients at high risk of recurrence, the possible benefits of
this dosing regimen appear to outweigh the possible risks.
Objectives of the present trial
To determine whether administration of a loading dose of
oral vitamin D3 (500,000 IU) followed by a monthly tablet
of 50,000 IU of oral vitamin D3 for 2 years following
primary treatment of melanoma at high risk of recurrence:
1. achieves maintenance of serum 25 hydroxyvitamin
D concentrations above 80 nmol/l in patients who
receive active treatment
2. achieves > 80% adherence to dosing rates during
2 years of study treatment3. achieves adequate recruitment rates (75 patients in
2 years from one site)
4. produces no clinically significant difference in
hypercalcaemia incidence between the active and
placebo groups
5. produces no clinically significant difference in renal
function between the active and placebo groups
6. produces no clinically significant difference in the
incidence of renal calculi between the active and
placebo groupsPrimary endpoints
The primary endpoints will be met if the following cri-
teria are achieved:
1. Dose sufficiencyIf the majority of treated patients achieve a serum
25OHD of 80 nmol/l at both 12 and 24 months
and the average serum 25OHD for treated patients
is > 75 nmol/l at 12 and 24 months
2. Dose adherence
If patients take > 80% of the prescribed monthly dose
3. Safety
Calcium [40]
■ If the mean serum calcium concentration in
each patient is <2.75 mmol/L (11 mg/dL) over
the course of the study.
■ If there is no increase in the prevalence of
hypercalcaemia relative to the baseline
prevalence.
■ If the urine calcium excretion in each patient
is less than 7.5 mmol/24 h OR the mean
urinary calcium-creatinine ratio in each patient
is <1.0 (when calcium and creatinine are
measured in mmol) over the course of the
study.
■ If there is no increase in the prevalence of
hypercalciuria relative to the baseline
prevalence.
Kidney function
■ If there is no greater than a 20% fall in the
average estimated GFR [GFR = 186.3 ×
SerumCr-1.154 × age-0.203 × 1.212 (if patient is
black) × 0.742 (if female) – MDRD formula
(21)] over the course of the study.
■ If the average eGFR at the end of the study is
no more than 20% less in vitamin D treated
patients than in placebo treated patients.
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If no more than two episodes of renal calculus
occurs in vitamin D treated patients during the
course of the study.Secondary endpoints
The secondary endpoints will be met if the following
criteria are achieved:
1. If 60% of eligible patients agree to participate and
the study accrues 75 patients in 2 years.
2. Improved progression free survival.
Other tests
A sample of baseline blood will be stored for later
extraction of DNA and possible testing for gene variants
(e.g. in the vitamin D receptor gene or the vitamin D
binding protein gene) that may influence vitamin D
activity to see if they influence plasma vitamin D response
to therapy or melanoma recurrence.
Methods/Design
Trial design
This is a multi-center placebo controlled randomised
phase II trial which aims to evaluate the safety and efficacy
of high dose vitamin D therapy in patients who have been
treated for primary melanoma and are at high risk of
recurrence. Patients will receive treatment at Melanoma
Institute Australia (MIA) (at the Poche Centre or at
the Royal Prince Alfred Hospital (RPAH)), or other
participating melanoma study centres.
Participants
Eligible participants are patients aged 18 – 79 who have
completed primary (surgical) treatment for cutaneous
melanoma and are considered to be at high risk for
recurrence: AJCC Stage IIb, IIc, IIIa (N1a, N2a), IIIb
(N1a, N2a), that is, patients with ulcerated tumors
thicker than 2 mm or with tumors thicker than 4 mm or
those with nodal micro-metastases. Comprehensive in-
clusion and exclusion criteria are found in Appendix 1.
Intervention
a) Materials
Study medications will be provided under the
Australian Therapeutic Goods Administration
Clinical Trials Notification scheme. Patients
randomised to the active treatment arm will receive
Cal.D.Forte tablets containing 50,000 IU of
cholecalciferol from API Consumer Brands New
Zealand. Patients randomised to the placebo arm
will receive placebo tablets from a batch prepared by
API for an unrelated study and provided by thatstudy’s coordinator, Dr Anna Ralph, of the Menzies
School of Health Research, Darwin.
b) Study drug administration
Patients will receive oral vitamin D (Cal.D.Forte)
tablets containing 50,000 IU of cholecalciferol from
API Consumer Brands New Zealand or matching
placebo.
Following confirmation of eligibility and
randomisation, patients randomized to active
treatment will receive 500,000 IU of cholecalciferol
(Vitamin D3) orally (10 tablets to be administered by
the study team during the initial baseline study visit).
Thereafter, patients will self-administer 50,000 IU, 1
Cal.D.Forte tablet on the 1st day of each month




The short term effects of high dose vitamin D
therapy will be assessed by conduct of the following
assays and diagnostic tests:
Renal and liver function tests (including estimated
Glomerular Filtration Rate (eGFR) and urine
calcium/creatinine ratio)
Serum 25OHD levels
Serum corrected calcium, 24 hour urinary calcium
excretion or urinary calcium to creatinine ratio.
The scheduling of these assessments is found in
Table 1.
b) Adherence
Patients will be asked to keep a diary to record their
use of the study drug. These diaries will be reviewed
four monthly at each patient follow-up visit.
The study team will confirm adherence to the
treatment regime by contacting study patients at
interim time points during the treatment phase and
also during clinic follow-up visits at 4, 8, 12, 16, 20
and 24 months. To help improve adherence,
monthly SMS text messages will be sent to those
patients with mobile phones, reminding them to
take their study tablets.
In the event of a missed dose, patients will be able
to take the missed dose at the following clinic visit.
Appropriate procedures will be established to
facilitate this while ensuring maintenance of
necessary “blindness” with respect to the
intervention arm each participant is in.
c) Safety
The feasibility, safety and short term effects of high
dose vitamin D therapy will be assessed by the
conduct of the assays and diagnostic tests found in
Table 3.
Table 3 Schedule of assessments
Baseline 4-6 wks 4 mth 8 mth 12 mth 16 mth 20 mth 24 mth
History X X X X X X X
Body mass index/height cm X X X X X X X
Serum corrected calcium X X X X X X X X
Phosphate X X X X X X X X
24 hour urinary calcium (preferred) X X X
Urinary calcium/creatinine ratio(for first 3 time points
only if 24 h urine unavailable)
X X X X X X X X
Serum25O D X X X X X
FBC X X X X
LFTs X X X X
eGFR X X X X
Adherence to dosing regime X X X X X X X
Tumour status X X X X X X X
Note: Serum corrected calcium requires serum albumin.
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ise relevant to vitamin D and its effects has been
appointed to adjudicate on all matters of patient safety.
The monitor will be informed immediately if a result of
any of the above tests is considered to be clinically sig-
nificant (as determined by a local clinician) and will spe-
cify the action to be taken with respect to that result in
the patient’s interest. Actions include dose modification,
dose cessation and withdrawal from the trial because of
low serum 25OHD concentration (see Appendix 2 for
details).
Sample size and randomisation
The design of the study is an optimal two-stage phase
II trial using the approach of Simon [41]. Sample sizes
are determined separately for the two cohorts. The two
cohorts, those receiving vitamin D and those receiving
placebo, will be analysed separately. Assuming a lower
limit of efficacy of 48% and a regimen activity level of
68%, the study would proceed in two stages. In the first
stage, if more than 7 patients with serum 25OHD less
than 80 nmol/l are observed in the first 14 patients in
the active arm, consideration will be given to either
modifying the regimen or stopping the study due to
inactivity.
Twenty-five patients (in a 2:1 randomisation) will be
accrued to the placebo arm to allow adequate data to
estimate concentration of serum 25OHD in an
untreated cohort. Thus it is proposed to accrue a total
of 75 patients into the study, 50 receiving vitamin D
and 25 receiving placebo. These calculations are based
on power of 80% with 95% confidence and allow for a
modest dropout rate.
Patients will be centrally randomised by the Australian
National Health and Medical Research Council (NHMRC)Clinical Trials Centre using a computerised interactive
voice response system (IVRS). Patients will be stratified by
gender.Accrual rate
The anticipated accrual rate is 75 patients in 2 years.
Progression free survival
Analysis of the secondary endpoint of improved pro-
gression free survival will take into account patient
stage subgroups. However, as the numbers in this study
are small, a meaningful subgroup analysis may not be
possible.
Participant follow-up
Participation in this study is voluntary; patients will be
able to withdraw at any time. Patients will be asked to
present for clinical follow-up four monthly for the two
years following treatment of their primary melanoma.
Those who withdraw from treatment will be asked to
continue follow-up visits according to the protocol even
though they have stopped treatment, to allow collection
of outcome data. If a patient decides to stop their
follow-up visits, their health status will be periodically
ascertained by way of phone contact with their general
practitioner or by direct phone contact. The National
Death Index at the Australian Institute of Health and
Welfare will be used to collect survival information on
patients who have been lost to follow-up.
After completion of active follow-up, recurrences
will be ascertained through the New South Wales
Central Cancer Registry and deaths through the National
Death Index for a period of five years after date of
diagnosis.
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Patients and physicians are blinded to both study treatment
allocation and vitamin D levels.
Statistical methods
a) Analysis of primary endpoints
The percentage of patients achieving a serum
25OHD above 80 nmol/l at 12 and 24 months
receiving treatment will be reported. Summary
statistics of serum 25OHD concentrations will be
reported for both groups at 12 and 24 months.
Dose adherence will be reported as the percentage
of dose taken compared to the prescribed monthly
dose as calculated from the patient diary and study
forms. A 95% confidence interval will be reported to
check if the expected rate of 80% dosage of study
tablets for the duration of the study protocol by all
patients is obtained.
Safety outcomes will be reported as the proportions
of patients exceeding the following maxima, as well
as summary statistics where appropriate.
b) Analysis of secondary endpoints
Participation rate will be reported as the proportion
of subjects eligible and invited to participate who
agree to be randomised. A 95% confidence interval
will be reported to check if the expected rate of 60%
was obtained.
Progression free survival will be displayed using
Kaplan-Meier survival curves.
Quality assurance
An independent Data Safety Monitoring Committee will
periodically review the study for efficacy and safety. Efficacy
will be reviewed after the first 14 patients in the active arm
have completed 4 and 12 months of the vitamin D regimen.
Safety data will be reviewed after 20 patients have
completed 4 and 12 months of treatment and again when
35 patients have completed 12 months of treatment.
Discussion
Feasibility
Initial accrual to the ANZMTG 02.09 Mel-D study was
slow, however a number of strategies have recently
worked well in the early identification of eligible
patients. All histopathology reports from wide excisions
of melanoma are checked by the clinical trials staff and
potentially eligible study participants are identified. The
melanoma surgeons are reminded about study eligibility
criteria prior to that patient’s consultation. In addition, a
one-page Mel-D trial synopsis detailing the inclusion
and exclusion criteria has been placed in the surgical
consulting rooms and frequent updates of the trial
progress are reported at the MIA research meetings.The study is promoted regularly on the ANZMTG
website, membership newsletter and at various meetings
(including the Annual Scientific Research Meeting).
Approximately 50% of eligible patients have participated
in the study. The target accrual of 75 patients has been
achieved and 21 patients have completed the full 24
months of treatment and follow-up. However, 10 patients
have developed recurrence and ceased the trial. Planning
for a phase III trial is underway, to open to melanoma
treatment sites outside the Melanoma Institute Australia.
Registration
This trial is registered with the Australia and New Zealand
Clinical Trials Registry (ANZCTR) #ACTRN12609000351
213.
Protocol
A full copy of the current ANZMTG 02.09 Mel-D protocol
can be requested from the principal investigator Dr Robyn
Saw, email: robyn.saw@melanoma.org.au.
Appendix 1
Comprehensive inclusion and exclusion criteria for
ANZMTG 02.09 Mel-D study
Inclusion criteria
1. 18–79 years of age.
2. Primary, histologically confirmed resected stage IIb,
IIc, IIIa (N1a, N2a) and IIIb (N1a, N2a) cutaneous
melanoma.
3. Wide excision or, if there is no wide excision,
excision of the primary lesion with clear pathological
margins <120 days prior to randomisation, with or
without sentinel node biopsy.
4. Serum corrected calcium and Serum creatinine are
≤1.5 times the institutional upper limit of normal
and eGFR within normal range for testing laboratory.
5. Serum lactate dehydrogenase < 1.5 upper limit of
normal.
6. Written informed consent.
7. Geographically accessible and willing and able to
attend 4 monthly follow-up at MIA for 2 years.
8. Performance status ECOG 0–2 (see Appendix 1).
Exclusion criteria
1. Patients with a known history of renal calculi.
2. Patients with a known history of
hyperparathyroidism.
3. Patients who have a concomitant invasive cancer
other than basal cell carcinoma of the skin or
localized squamous cell carcinoma of the skin or a
previous such cancer and have been cancer free for
less than 5 years.
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must not have been carried out more than four
weeks prior to randomisation)
Absolute neutrophil count < 1.5 × 109/L
Platelet count < 100 × 109/L
Total bilirubin > 1.5 upper limit of normal
AST, ALT, Alk Phos > 2.5 upper limit of normal
5. Patients who are pregnant or lactating. Women of
child bearing potential must have a confirmed
negative pregnancy test at study entry.
6. Patients with a medical or psychosocial problem
which, in the investigators opinion, would interfere
with treatment or follow-up.
7. Patients with either ocular or mucosal melanoma.
8. Patients who are currently enrolled in trials of other
experimental treatments or alternative therapies.
9. Patients cannot have received any other.
investigational agents or treatments (i.e. chemo-,
immuno-, vaccine or radiotherapy) within 30 days
of commencing study.
10. Patient should not be taking other agents known
to interact with the study drug, such as
anti-convulsants.Appendix 2
Safety procedures in the event of abnormal assay results
Dose modification
■ If serum 25OHD is >200 nmol/l 4–6 weeks after the
first dose is given, discontinue all treatment and
recommence monthly treatment if and when it falls to
<120 nmol/l on 4 monthly monitoring.
■ If serum corrected calcium, 24 hour urinary calcium
excretion or urinary calcium to creatinine ratio is
above the normal range by <20% of the upper limit of
normal, discontinue treatment until it returns to
within the normal range, then recommence monthly
treatment. In the event of temporary discontinuation
for either of these reasons, measure 25OHD on
stored serum from blood sample collected at the time
of the elevated calcium or calcium to creatinine ratio
if not a routine 25OHD measurement time.Dose cessation
■ eGFR, serum corrected calcium, 24 hour urinary
calcium excretion, or calcium to creatinine ratio is
>20% above laboratory normal range.
■ Development of a renal calculus while on study
treatment.
■ Pregnancy occurring during the course of the trial.
■ Disease progression.Withdrawal because of low serum 25OHD concentration
If a patient is found to have a serum 25OHD con-
centration of <25 nmol/l at any time it is assayed, he
or she will be withdrawn from the trial and offered
vitamin D replacement therapy. Because of the desir-
ability of batching vitamin D assays, serum collected
at baseline and 4 months will be assayed in a single
batch, as will that collected at 12 and 24 months.
Neither patients nor their doctors will be told that
patients should not take vitamin D supplements du-
ring the trial, or have their serum vitamin D concen-
tration assayed if it is clinically indicated. Patients will
be asked about use of vitamin D supplements or the-
rapy at each clinic visit.
Concomitant medications/treatments
Concomitant medications will not be recorded during
the study, except for medications used to treat ad-
verse events or medications known to interact with
the study medications.
■ Anti-convulsant medication is not allowed.
■ Any concomitant use of vitamin D or multi-vitamin
supplements in sufficient detail to be able to esti-
mate daily vitamin D intake from these sources.
■ Any concomitant use of calcium supplements.
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